CD274 and non-small cell lung carcinoma: Therefore, in our study, we aimed at determining VTE incidence in NSCLC patients treated with the association of chemotherapy and immunotherapy (CT-IO) in first-line and to assess if PD-L1 is an independent risk factor of VTE.